Legato Capital Management LLC Raises Stock Position in Xenon Pharmaceuticals Inc. $XENE

Legato Capital Management LLC increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 160.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 37,038 shares of the biopharmaceutical company’s stock after purchasing an additional 22,829 shares during the quarter. Legato Capital Management LLC’s holdings in Xenon Pharmaceuticals were worth $1,660,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in XENE. Danske Bank A S purchased a new stake in Xenon Pharmaceuticals in the third quarter worth approximately $32,000. Blue Trust Inc. boosted its stake in shares of Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new position in shares of Xenon Pharmaceuticals during the 3rd quarter worth $39,000. Osaic Holdings Inc. boosted its stake in shares of Xenon Pharmaceuticals by 541.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares during the last quarter. Finally, State of Wyoming boosted its stake in shares of Xenon Pharmaceuticals by 112.8% during the 3rd quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 610 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Performance

XENE opened at $54.17 on Friday. Xenon Pharmaceuticals Inc. has a fifty-two week low of $28.19 and a fifty-two week high of $63.95. The firm’s fifty day moving average is $56.15 and its 200 day moving average is $47.56. The stock has a market cap of $5.24 billion, a price-to-earnings ratio of -11.53 and a beta of 0.65.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same quarter in the previous year, the firm posted ($0.83) EPS. On average, equities research analysts predict that Xenon Pharmaceuticals Inc. will post -4.88 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Robert W. Baird lifted their price target on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, March 9th. Morgan Stanley set a $97.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Guggenheim reiterated a “buy” rating and set a $90.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Royal Bank Of Canada lifted their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Finally, Needham & Company LLC dropped their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $77.07.

Insider Activity at Xenon Pharmaceuticals

In related news, insider Christopher John Kenney sold 2,771 shares of Xenon Pharmaceuticals stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total transaction of $166,564.81. Following the transaction, the insider owned 4,729 shares in the company, valued at approximately $284,260.19. The trade was a 36.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ian Mortimer sold 270,000 shares of Xenon Pharmaceuticals stock in a transaction on Monday, March 9th. The shares were sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the transaction, the chief executive officer owned 6,000 shares in the company, valued at approximately $361,980. This trade represents a 97.83% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 296,707 shares of company stock worth $17,845,365. 4.07% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.